Article Text

Download PDFPDF
Excessive daytime sleepiness: an emerging marker of cardiovascular risk
  1. Joshua Bock,
  2. Naima Covassin,
  3. Virend Somers
  1. Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA
  1. Correspondence to Dr Virend Somers, Mayo Clinic Rochester, Rochester, MN 55901, USA; somers.virend{at}mayo.edu

Abstract

Excessive daytime sleepiness (EDS) is classically viewed as a consequence of insufficient sleep or a symptom of sleep disorders. Epidemiological and clinical evidence have shown that patients reporting EDS in tandem with sleep disorders (e.g., obstructive sleep apnoea) are at greater cardiovascular risk than non-sleepy patients. While this may simply be attributable to EDS being present in patients with a more severe condition, treatment of sleep disorders does not consistently alleviate EDS, indicating potential aetiological differences. Moreover, not all patients with sleep disorders report EDS, and daytime sleepiness may be present even in the absence of any identifiable sleep disorder; thus, EDS could represent an independent pathophysiology. The purpose of this review is twofold: first, to highlight evidence that EDS increases cardiovascular risk in the presence of sleep disorders such as obstructive sleep apnoea, narcolepsy and idiopathic hypersomnia and second, to propose the notion that EDS may also increase cardiovascular risk in the absence of known sleep disorders, as supported by some epidemiological and observational data. We further highlight preliminary evidence suggesting systemic inflammation, which could be attributable to dysfunction of the gut microbiome and adipose tissue, as well as deleterious epigenetic changes, may promote EDS while also increasing cardiovascular risk; however, these pathways may be reciprocal and/or circumstantial. Additionally, gaps within the literature are noted followed by directions for future research.

  • hypertension
  • inflammation
  • obesity

Statistics from Altmetric.com

Footnotes

  • Contributors JB drafted the initial manuscript and critically revised its content. NC and VS revised the manuscript providing significant intellectual contributions.

  • Funding JB is funded by the National Institutes of Health grant T32-HL007111. NC is supported by the National Institutes of Health grants HL134885 and HL134808, Mayo Clinic Marie Ingalls Research Career Development Award and a grant from Sleep Number Corporation to Mayo Clinic. VS is funded by the National Institutes of Health grants HL134885 and HL065176 as well as a grant from Sleep Number Corporation to Mayo Clinic for studies of the cardiovascular implications of sleepiness.

  • Competing interests VS has consulted for Baker Tilly, Respicardia, Bayer and Jazz Pharmaceuticals, and is on the Scientific Advisory Board for Sleep Number Corporation.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.